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Carcinosarcoma of the bladder is an unusual tumour characterized by a combination of malignant epithelial and soft tissue
elements. Most of the reported cases have been case reports or small series. Optimal treatment is uncertain. We herein report
our experience in such a case treated with transurethral resection followed by radiotherapy with adverse ﬁnal outcome. Treatment
of bladder carcinosarcomas should be aggressive and multimodal but optional treatment is still unknown. Radiotherapy alone is
insuﬃcient as a treatment option of these aggressive tumors.
1.Introduction
Carcinosarcomas (CSs) of bladder cancer are rare tumors
and consist of a combination of malignant epithelial and
sarcomatoid components. They are more common in males
than females with a ratio nearly 2:1. The most common
age at presentation is the seventh decade of life [1].
Usual presentation is that of macroscopic hematuria and
dysuria. Risk factors include previous pelvic radiation and
cyclophosphamide therapy. Generally more than 70% of CSs
present with advanced stage and have a worse prognosis than
conventional urothelial carcinomas [1].
Hereby, we present a case of urinary bladder CS with
mesenchymal elements of osteosarcoma and chondrosar-
coma which received adjuvant radiotherapy after transure-
thral resection with no response, and we review the recent
literature.
2. Case Presentation
A 76-year-old female with a past medical history of heart
failureandnon-insulin-depenentdiabetesmellituspresented
with a two-week history of total heamaturia and dysuria.
Physical examination was unremarkable. Abdominal ultra-
sound revealed a mass located on the right lateral wall
of the urinary bladder. Rigid cystoscopy revealed a 4-5cm
hemorrhagic, exophytic, and invasive lesion occupying the
right lateral bladder wall and ureteral oriﬁce. Computerized
tomography (CT) of the abdomen showed a soft tissue
mass with multiple calciﬁed foci in the right bladder wall,
extending posterior with dilation of the ipsilateral ureter.
CT of the chest and bone scan was negative for metastases.
The clinical stage was cT3N0M0. The patient underwent
transurethral resection of the tumor. Histopathology of the
specimen revealed bladder CS invading the bladder muscle.
The epithelial component was high-grade urothelial cancer,
and the sarcomatoid element consisted of osteosarcoma and
chondrosarcoma (Figure 1). The patient made an uneventful
recovery. Radical cystectomy was deemed too high risk due
to severe heart failure of the patient and the local extension
of the disease. The patient was treated with 50Gy of 3D
conformal radiotherapy but unfortunately did not complete
the protocol due to progression of the disease. She developed
renal failure and died ﬁve months later.2 Case Reports in Urology
Figure1:Theepithelioidandsarcomatoidcomponentofthetumor
showing polygonal cells and spindle cells, respectively. There is
focal appearance of osteosarcoma cells (hematoxylin-eosin, original
magniﬁcation ×400).
3. Discussion
The histological features of CS of the bladder vary. Macro-
scopically these tumors are usually large, polypoid or
nodular. Most reported cases contain high-grade papil-
lary/undiﬀerentiated urothelial carcinoma although other
subtypes like small-cell carcinoma, squamous carcinoma,
andadenocarcinomahavebeenreported.Themostcommon
sarcomatous elements are chondrosarcoma, leiomyosar-
coma, and malignant ﬁbrous histiocytoma. In our case the
sarcomatous element was a mixture of chondrosarcoma and
osteosarcoma.
There is considerable confusion and disagreement in the
literature regarding nomenclature. In some series, both CS
and sarcomatoid carcinoma (SC) are included as “sarcoma-
toid carcinoma” and these terms are used interchangeably
[2]. In others they are regarded as separate entities [1]. An
interest study by Wright et al. showed a diﬀerent survival
rate between patients with CS and SC (5-year survival
rate 17% versus 37%), oﬀering some justiﬁcation for the
continued diﬀerentiation of these tumor types for clinical
prognostication [1].
Diﬀerential diagnosis should also be considered with
urothelial carcinomas with osseous metaplasia, primary
osteogenic sarcoma, especially if the sarcomatous elements
in the former condition produce osteoid and nonneoplastic
conditions like encrusted cystitis and polypoid cystitis glan-
dularis.
CS carries a dismal prognosis with a median cancer-
speciﬁc survival of 14 months (95% CI 7–21 months) [3].
Many series emphasize the importance of stage for the
prognosis [1,3,4].Halfofpatients diewithin1yearfromthe
diagnosis. However, in a case series study none of 8 patients
with pT1 disease died of the disease, although followup was
incomplete in 3 of them [4].
Due to rarity of the tumor, all the treatment results are
from case reports and small case series [2, 5]. A variety
of treatment modalities have been described but optimal
Table 1: Treatment modalities for the bladder carcinosarcoma.
Transurethral resection
Transurethral resection + radiation
Transurethral resection + radiation + chemotherapy
Cystectomy
Cystectomy + radiation
Cystectomy + radiation + chemotherapy
Partial cystectomy
treatment requires rather a multimodality therapy (Table 1).
Transurethral resection and partial cystectomy carry the
risk of incomplete tumor resection. Radical cystectomy
with pelvic lymphadenectomy is the mainstay of treatment
[1], although patients tend to develop local recurrence
after surgery [1, 3] .I nar e c e n ts t u d yw h i c ha n a l y z e d
retrospectively 221 cases the overall 5-year cancer-speciﬁc
survival rate after cystectomy was only 20.3%, suggesting a
high risk of early dissemination [3]. Cancer-speciﬁc survival
was signiﬁcantly better for those who underwent cystectomy
instead of transurethral resection [3].
Adjuvant radiotherapy and various combinations of
chemotherapy have yielded inconsistent results. In the study
byWrightetal.asmallcohortof9patientsreceivedradiation
after transurethral resection but subgroup survival analysis
was not available. Radiotherapy alone is rather insuﬃcient
as it was shown in our case. In our opinion poor treatment
results are also due to either the advanced stage of the disease
or the poor status of the patients selected for radiotherapy
as they are not candidates for more aggressive treatment.
Carboplatin andgemcitabinehavebeenusedincombination
with radiotherapy with promising results considering that
traditional standard treatment for most sarcomas show poor
response to primary radiation therapy [6–9].
4. Conclusion
Treatment of bladder carcinosarcomas should be aggressive
and multimodal but optional treatment is still unknown.
Radiotherapy alone is insuﬃcient as a treatment option of
these aggressive tumors.
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